CN116570594A - 选择性p38α特异性MAPK抑制剂 - Google Patents

选择性p38α特异性MAPK抑制剂 Download PDF

Info

Publication number
CN116570594A
CN116570594A CN202310509095.9A CN202310509095A CN116570594A CN 116570594 A CN116570594 A CN 116570594A CN 202310509095 A CN202310509095 A CN 202310509095A CN 116570594 A CN116570594 A CN 116570594A
Authority
CN
China
Prior art keywords
cancer
mapk
formula
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310509095.9A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·夏皮罗
杰弗里·哈斯戴
亚历山大·麦克莱尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland, Baltimore
Office of General Counsel of VA
Original Assignee
University of Maryland, Baltimore
Office of General Counsel of VA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland, Baltimore, Office of General Counsel of VA filed Critical University of Maryland, Baltimore
Publication of CN116570594A publication Critical patent/CN116570594A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202310509095.9A 2016-06-23 2017-06-22 选择性p38α特异性MAPK抑制剂 Pending CN116570594A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662353856P 2016-06-23 2016-06-23
US62/353,856 2016-06-23
US201762469913P 2017-03-10 2017-03-10
US62/469,913 2017-03-10
PCT/US2017/038697 WO2017223284A1 (en) 2016-06-23 2017-06-22 NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF
CN201780051906.8A CN109640970B (zh) 2016-06-23 2017-06-22 选择性p38α特异性MAPK抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780051906.8A Division CN109640970B (zh) 2016-06-23 2017-06-22 选择性p38α特异性MAPK抑制剂

Publications (1)

Publication Number Publication Date
CN116570594A true CN116570594A (zh) 2023-08-11

Family

ID=60784745

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310509095.9A Pending CN116570594A (zh) 2016-06-23 2017-06-22 选择性p38α特异性MAPK抑制剂
CN201780051906.8A Active CN109640970B (zh) 2016-06-23 2017-06-22 选择性p38α特异性MAPK抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780051906.8A Active CN109640970B (zh) 2016-06-23 2017-06-22 选择性p38α特异性MAPK抑制剂

Country Status (6)

Country Link
US (5) US20190151324A1 (cg-RX-API-DMAC7.html)
EP (1) EP3474835B1 (cg-RX-API-DMAC7.html)
JP (2) JP7013453B2 (cg-RX-API-DMAC7.html)
CN (2) CN116570594A (cg-RX-API-DMAC7.html)
AU (4) AU2017281222B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017223284A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116570594A (zh) 2016-06-23 2023-08-11 马里兰大学巴尔的摩分校 选择性p38α特异性MAPK抑制剂
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ATP/触媒部位p38マイトジェン活性化プロテインキナーゼ阻害剤
US20230140941A1 (en) * 2020-03-13 2023-05-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
CN116406355B (zh) 2020-05-18 2026-05-15 Gen1E生命科学公司 P38α促分裂原活化蛋白激酶抑制剂
AU2021370893B2 (en) 2020-10-29 2024-03-07 Gen1E Lifesciences Inc. Crystalline 5-(dimethylamino) -n- (4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
NZ804686A (en) 2021-03-23 2026-03-27 Gen1E Lifesciences Inc Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
US20250093263A1 (en) * 2021-07-22 2025-03-20 The General Hospital Corporation Fret-based assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR96352E (fr) 1967-12-29 1972-06-16 Science Union & Cie Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
DE19801646A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
JPH11269146A (ja) 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
RU2380369C9 (ru) 2002-09-04 2011-07-10 Шеринг Корпорейшн Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
AU2004212043A1 (en) 2003-02-13 2004-08-26 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino(1,2-a)pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
WO2005100338A1 (en) 2004-04-13 2005-10-27 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
US7297817B2 (en) 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
EP1868616A2 (en) * 2005-03-29 2007-12-26 The University of Maryland, Baltimore Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor
TW200904421A (en) * 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
ES2427892T3 (es) 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
AU2009313315A1 (en) 2008-11-07 2011-06-30 The Cleveland Clinic Foundation Compounds and methods of promoting oligodendrocyte precursor differentiation
WO2010082912A1 (en) * 2009-01-15 2010-07-22 Avalon Pharmaceuticals Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
CN105308004A (zh) 2013-01-15 2016-02-03 卡尔·亚历克斯·穆勒 利用紫外线辐射的氧化物的快速固态反应
EP3004087B1 (en) * 2013-06-06 2017-08-09 CHIESI FARMACEUTICI S.p.A. Derivatives of [1,2,4]triazolo[4,3-a]pyridine as p38-map kinase inhibitors
US9025712B2 (en) 2013-07-30 2015-05-05 Pixart Imaging Inc. Sensor, clock frequency adjusting system and method thereof
ES2774249T3 (es) * 2014-02-14 2020-07-20 Respivert Ltd Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
GB201417168D0 (en) 2014-09-29 2014-11-12 Univ Hertfordshire Higher Education Corp Compounds
JP2017538676A (ja) * 2014-11-05 2017-12-28 ザ ユニバーシティ オブ カンザス ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤
CN116570594A (zh) * 2016-06-23 2023-08-11 马里兰大学巴尔的摩分校 选择性p38α特异性MAPK抑制剂
TW201829381A (zh) 2016-12-22 2018-08-16 美商拜奧馬林製藥公司 組蛋白脫乙醯基酶抑制劑
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ATP/触媒部位p38マイトジェン活性化プロテインキナーゼ阻害剤
US20230140941A1 (en) 2020-03-13 2023-05-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
CN116406355B (zh) 2020-05-18 2026-05-15 Gen1E生命科学公司 P38α促分裂原活化蛋白激酶抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIAVA M ET AL.: "Synthesis and antimycobacterial activity of new amido derivatives of ortho-,meta- and para-toluidine", 《MEDICINAL CHEMISTRY RESEARCH》, vol. 8, no. 9, 1 January 1998 (1998-01-01), pages 527 - 531 *
STN: "697229-25-7", 《数据库REGISTRY》, 22 June 2004 (2004-06-22), pages 1 *

Also Published As

Publication number Publication date
US20230201211A1 (en) 2023-06-29
AU2022218616B2 (en) 2024-02-29
US11911393B2 (en) 2024-02-27
US20190151324A1 (en) 2019-05-23
EP3474835A1 (en) 2019-05-01
AU2017281222A1 (en) 2019-01-24
WO2017223284A1 (en) 2017-12-28
JP7372993B2 (ja) 2023-11-01
AU2024202879B2 (en) 2025-08-14
US20240366619A1 (en) 2024-11-07
US11911392B2 (en) 2024-02-27
EP3474835C0 (en) 2023-07-05
US20220331329A1 (en) 2022-10-20
AU2017281222B2 (en) 2022-06-16
AU2025259977A1 (en) 2025-11-20
AU2024202879A1 (en) 2024-05-23
JP2022046803A (ja) 2022-03-23
CN109640970B (zh) 2023-05-23
AU2022218616A1 (en) 2022-09-15
CN109640970A (zh) 2019-04-16
US11357781B2 (en) 2022-06-14
US20210267987A1 (en) 2021-09-02
JP2019527239A (ja) 2019-09-26
EP3474835B1 (en) 2023-07-05
JP7013453B2 (ja) 2022-01-31
EP3474835A4 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CN113395963B (zh) 非ATP/催化位点p38丝裂原活化蛋白激酶抑制剂
CN109640970B (zh) 选择性p38α特异性MAPK抑制剂
WO2021183970A1 (en) Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
HK40097461A (en) SELECTIVE P38α-SPECIFIC MAPK INHIBITORS
HK40060133B (en) Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
HK40060133A (en) Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40097461

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20230811

RJ01 Rejection of invention patent application after publication